VANCOUVER, British Columbia / ACCESSWIRE / February 15, 2022 / Gemina Laboratories Ltd. (CSE: GLAB) (FRA: 8I7) (“The company“or”The twins“) is pleased to present the following strategic review and share projections for 2022 and beyond.
Gemini Chemistry Platform
The company is based on Gemina’s breakthrough chemistry, which underpins the development of next-generation diagnostics and biosensors for human health and well-being. Gemina has made significant and substantial progress in testing its first application of the technology, namely its surface chemistry platform for rapid testing on COVID-19. The Gemina platform technology has potential applications for a wide range of health issues, including cancer, heart health, inflammation and tropical diseases. In the context of people’s well-being, Gemina is exploring a variety of applications, from monitoring stress and anxiety to monitoring nutrition and exercise and recovery testing.
The company believes that its surface chemistry platform can provide a variety of medical and consumer rapid tests in a variety of form factors. To this end, Gemina has focused on two main outcomes – proving the viability of the platform through independent laboratory tests and establishing the commercial viability of the platform. In doing so, the research and development team of the company expanded its IP portfolio by filing a patent application to cover the extended family of chemical surfaces, which includes seven iterations of development. The platform is applied to a number of conventional sensor substrates (e.g., gold, silica, cellulose, polymers) and can be tuned to capture a variety of biological targets (including proteins and nucleotides).
Gemina’s first product using our chemical platform is a rapid diagnostic test aimed at the SARS CoV-2 antigen. This product development path is nearing completion of Phase 1 production research and it has now reached a freeze project for nasal fluid-based analysis, and is currently being performed at or below the detection limit required to submit regulatory documents based on fictional samples enriched with inactivated virus. These results are comparable to our previously announced positive results for saliva-based trials. The company views this use case as a strong proof of the commercial concept of a basic chemical platform that promises to provide accurate, powerful, fast and cost-effective diagnostics at the right time. Full coverage of the progress to date and the expected stages of our test for SARS CoV-2 can be found in our press release of February 3, 2020.
Development of next generation devices
Better chemistry requires better device technology. To take full advantage of Gemina chemistry, the company is committed to combining it with new patented device technologies that enable physicians and consumers to obtain fast and accurate data related to their health and well-being. Gemina’s business can take advantage of the growing demand for affordable and rapid sensing in need (a trend in human health markets sometimes referred to as “democratization of diagnosticsThe COVID-19 pandemic brought rapid tests to the service point to the forefront of the public consciousness, but the trend of democratization of diagnostics was even before the pandemic. in vitro diagnostics market in 2021. Given the significant year-on-year growth from the pandemic, as well as growing comfort and convenience of rapid testing, the market is expected to increase in the coming years, and reports suggest that the global market could reach $ 93 billion by 2030, which is CAGR 11%.
While Gemina is currently creating qualitative rapid tests (of the type that display a simple positive or negative result), it aims to enhance the capabilities of rapid testing platforms where quantitative results are measured and displayed. The results may indicate the extent to which the target is present, or the amount of target marker present in the sample. In principle, quantitative rapid tests have significant potential for application in human health, offering indicators of markers indicating infection and disease, as well as markers indicating health and well-being. Such quantitative results will be useful for tracking time variability in biomarkers of stress and viability, for example, or in monitoring the detection of bacteria / pathogens in public places or food production facilities. Quantitative rapid tests are an important component of a company’s growth and value creation strategy. Gemina’s breakthrough chemistry relationship with patented devices that provide significant performance improvements over current products will not only improve market demand but also create significant value for shareholders.
Looking to 2022 and beyond
The focus in 2021 was the final development and independent testing of our chemical platform, as well as building the company’s fundamentals in terms of people, relationships and opportunities that will harness the unique nature of Gemina technology. This year, the team will focus on applying this chemistry to a wider range of real-world problems and ensuring the entry of our commercial products into the market. Our team also expects to grant additional patents, both for our chemical platform and for our patented devices, which will be the next generation of spot testing in various market segments.
Commenting on this progress, Rob Green, Gemina’s CTO, said: “Gemina’s chemical platform is capable of functionalizing biosensors in ways that were simply impossible in the past, and this opens the door to creating new types of tests on site. The potential here is huge. 2022 will be a very exciting year for us as we see Gemina evolving from its own chemical company. ”branded chemistry + branded device“a company that lays the foundation for highly differentiated solutions that will bring long-term success.”
On behalf of the Board of Directors
Gemina Laboratories Ltd.
About Gemina Laboratories Ltd.
Gemina Labs is a biosensory and diagnostic company with transformational, patented patented chemistry that provides next-generation platforms for testing a wide range of pathogens that affect human health and well-being. Our technology drives test platforms that are fast, affordable and accurate and easily managed on their own. Our development includes platforms for rapid testing for COVID-19, influenza and other viruses. More information about the company can be found at www.geminalabs.com.
Neither the Canadian Securities Exchange nor its regulatory service provider (as defined in the Canadian Securities Exchange Policy) assumes responsibility for the adequacy or accuracy of this Publication.
Statements about the future
This news release includes information about the future and statements that may include, but are not limited to, information and statements about future business, operations, financial performance, prospects and other plans, intentions, expectations, assessments and beliefs. companies. Such statements include statements regarding the intended terms of any proposed transaction or transaction. Information and statements that are not purely historical facts are statements that look to the future. Perspective information and statements include and are subject to assumptions and known and unknown risks, uncertainties and other factors that may cause actual events, results, performance or achievements of the company to differ materially from future events, results, performance, and achievements expressed or expressed. implied from forward-looking information and statements in this document. Although the Company believes that any forward-looking information and statements in this document are reasonable, in light of the use of assumptions and significant risks and uncertainties inherent in such information and statements, there can be no assurance that any such information and statements forward-looking information and statements will prove to be accurate, and accordingly, readers are encouraged to rely on their own assessment of such risks and uncertainties and should not rely unduly on such forward-looking information and statements. In addition, the Company is currently unable to fully assess the impact that the Covid-19 pandemic will have on its operations, and recognizes that certain cases may affect planned or projected performance. Therefore, any forward-looking information and statements in this document are made as of the date of this document, and, except as required by applicable law, the Company assumes no obligation and disclaims any intention to update or revise any forward-looking information and statements in this document. this document or update the reasons that actual events or outcomes may or do not differ from those projected in any information and statements projected in this document, as a result of new information, future events or outcomes or otherwise, except as provided current legislation.
For more information on company conversion, please contact:
SOURCE: Gemina Laboratories Ltd.
View original on accesswire.com: